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Abstract: The U.S. Preventive Services Task Force does not recommend routine screening for testicular
cancer (TC) in asymptomatic men, essentially because serological testicular cancer (TC) biomarkers
are not reliable. The main reason is that two of the most important TC biomarkers, α-fetoprotein (AFP)
and human chorionic gonadotropin (hCG), are not produced solely due to TC. Moreover, up to 40%
of patients with TC do not have elevated serological biomarkers, which is why serial imaging with
CT is the chief means of monitoring progress. On the other hand, exposure to radiation can lead to an
increased risk of secondary malignancies. This review provides the first comprehensive account of the
applicability of protein glycoprofiling as a promising biomarker for TC with applications in disease
diagnostics, monitoring and recurrence evaluation. The review first deals with the description and
classification of TC. Secondly, the limitations of current TC biomarkers such as hCG, AFP and lactate
dehydrogenase are provided together with an extensive overview of the glycosylation of hCG and
AFP related to TC. The final part of the review summarises the potential of glycan changes on either
hCG and AFP as TC biomarkers for diagnostics and prognostics purposes, and for disease recurrence
evaluation. Finally, an analysis of glycans in serum and tissues as TC biomarkers is also provided.
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1. Description, Risk Factors and Classification of Testicular Cancer (TC)
Cancer is either the first or second most common cause of death below the age of 70 in more than
half of 172 countries, according to the estimates from the World Health Organisation in 2015 [1]. It is
predicted that 9.6 million people died as a result of cancer and 18.1 million new cases were recorded
worldwide in 2018 [1]. Testicular cancer (TC) is relatively rare, but it is the most common solid tumour
found in young men [2,3].
1.1. TC Risk Factors
Recent studies suggest that TC is a result of interactions of multiple factors including environmental
and genetic ones, a claim supported by the study involving monozygotic/dizygotic twins [4,5].
Disrupted foetal hormone signalling during foetal development due to the influence of various
xenobiotics as well as misbalanced maternal hormone levels is thought to be the cause of multiple
disorders linked to TC [6–9]. A congenital defect, when one or both testicles are undescended into
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the scrotum (cryptorchidism), is connected with 5-fold increase of TC risk [3,10,11]. Furthermore,
inflammation of the testicles, for example, due to overcoming mumps and various testicular injuries
also has a negative effect [6]. Positive family history might be a strong risk factor, since the risk of
TC development increases when TC is diagnosed for direct blood relatives for men, like father and
brother [12,13]. When TC is diagnosed in one testis, there is a risk of the disease developing in the
opposite testis. The environmental impact on TC development and progression is supported by the
study concluding that sons of men who moved from a low- to a high-incidence place have the same risk
of TC as males living at a high-incidence place and the effect of harmful environmental factors can be
observed already in the 2nd generation [14]. Some information indicates that postnatal, environmental
and lifestyle (a diet and an exposure to endocrine disrupting agents) factors may negatively influence
the development of TC [15].
1.2. TC Classification
The rapid and efficient diagnosis, as well as the prognosis, is highly complicated due to the high
diversity of the disease. The most common first symptoms are changes in the area of the testicles.
There can be gradually growing lumps of solid consistency with a smooth, sometimes bumpy surface
that are detected by palpation randomly or during examination. Only 20% of patients suffer from pain,
which is described as a blunt pain and only accidentally as a severe pain with a risk of a tumour bleeding.
However, much more has been discovered by physicians in the investigation of patients who suffer
from testis and prostate atrophy, feminization, gynecomastia, hair loss or libido change due to hormonal
changes. TC is classified according to the histological tissue composition, the germ cell lineage and the
age at the onset of TC [3,16]. More than 90–95% of TC are germ cell tumours (GCTs) affecting testicular
germ cells (cells making sperms) [6,17]. The current WHO classification system defines two major
entities of GCTs as germ cell neoplasia in situ (GCNIS)-related and non-GCNIS-related (non-GCNIS)
(Figure 1) [3,16]. Approximately 60% of GCTs contain more than one type of histological pattern (i.e.,
mixed GCTs) [18].
The remaining TCs are of non-germ cell origin and include sex cord and gonadal stromal tumours,
lymphoid and hematopoietic tumours and metastatic tumours from other primary neoplasms [17,19,20].
From pure non-germ cell tumours, the largest occurrence has Leydig cell tumour (LCT), then Sertoli
cell tumour (SCT), granulosa cell tumour and pure stromal tumour [19,21].
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TC as early as possible to monitor the course of treatment or to predict the disease development [5]. 
Figure 1. Main types of testicular cancer (TC). GCTs = germ cell tumours, GCNIS = germ cell neoplasia
in situ.
2. TC Biomarkers and Their Limitations
The U.S. Preventive Services Task Force does not recommend routine screening for TC in
asymptomatic men [1]. Scrotal ultrasonography is the initial diagnostic tool in TC screening. After a
positive outcome from ultrasonography, when a solid intratesticular mass is discovered, orchiectomy
is applied for both diagnostic and therapeutic purposes. Finally, a process of staging through chest
radiography, chemistry panel, liver function tests and tumour markers guides the treatment of TC
patients [22].
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Since TC serological biomarkers are not reliable, it is essential to find a way to reliably diagnose
TC as early as possible to monitor the course of treatment or to predict the disease development [5].
Two of the most important TC biomarkers, α-fetoprotein (AFP) and human chorionic gonadotropin
(hCG), are not produced solely due to TC. The AFP level increases physiologically during the first
two years of life, but also in gastrointestinal or liver tissue tumours [23,24].The hCG value may be
elevated due to other cancer types, marijuana use, etc. [25–27]. In addition, these two biomarkers are
limited to some types of TC (AFP for yolk sac tumour and hCG for TC choriocarcinoma) (Table 1).
AFP and/or hCG are elevated in up to 70% of patients with non-seminomatous GCTs [28,29]. The third
biomarker, albeit less informative, is lactate dehydrogenase (LDH). Further, hCG is elevated in 15–30%
of seminoma patients at the time of diagnosis and LDH is elevated in up to 80% of patients with
advanced metastatic seminoma [28,29].
Table 1. Basic characteristics of currently used TC biomarkers. Update based on Ref. [18].
TC Biomarkers Half-Life Normal Values Tumour Type Glycoprotein Subunits
AFP 5–7 d < 40 ng/mL EC, T, YST 1 N-glycan1 O-glycan 1
hCG 24–36 h < 5 mIU/mL(0.6 ng/mL)
Seminoma, TC
choriocarcinoma, EC
4 N-glycans
4 O-glycans 2
LDH varies 1.5–3.2 nkat/mL Any - 4
AFP = α-fetoprotein, hCG = human chorionic gonadotropin, LDH = lactate dehydrogenase, EC = embryonal
carcinoma, YST = yolk sac tumour.
The levels of LDH, AFP and hCG are factors for the risk stratification of TC based on the
International Germ-Cell Cancer Collaborative Group classification [30]. It is known that up to 40% of
patients with TC do not exhibit elevated AFP, hCG or LDH levels. For these patients, serial imaging with
CT is the main means of monitoring the progress of the disease. On the other hand, a radiation load can
lead to an increased risk of secondary malignancies [31]. Accordingly, it is important to find biomarkers
that meet the following criteria: (1) adequate half-life with stability within the bloodstream; (2) the
presence in blood/urine in sufficient concentration; and (3) the presence in all TC types, irrespective of
age, the localisation and histological profile [32]. A full list of what is required for the biomolecules to
become a biomarker can be found elsewhere [33].
2.1. Human Chorionic Gonadotropin (hCG)
The protein, hCG, was discovered to be a biomarker of TC in 1938 [34]. Both subunits of hCG
(37 kDa) are heavily glycosylated (Table 1) with one third of the molecular mass of hCG consisting of
glycans [35]. Subunit α (92 amino acids) contains two N-glycans (Asn52 and Asn78) (Figure 2a) and
exhibits similarity with the follicle-stimulating hormone, luteinising hormone and thyroid-stimulating
hormone [18,36–39]. The larger subunit β (145 amino acids) contains two N-glycans (Asn13 and Asn30)
and 4 O-glycans (Ser121, Ser127, Ser132 and Ser138) (Figure 2a). Of those 4 O-glycans, three are type 1
O-glycans (Ser127, Ser132, and Ser138) and one is a type 2 O-glycan (Ser121) (Figure 2a). hCG and
some of its forms are one of the most acidic proteins in a human body with pI of 3.5 for hCG and pI of
3.2 for a hyperglycosylated hCG [40,41].
Hyperglycosylated hCG (hCG-H) is here defined as an hCG form recognised by the antibody B152,
i.e., having type 2 O-glycan on Ser132 of the β-subunit of hCG [42]. The malignancy-associated hCG-H
or hCGβ-H (β-subunit of hCG-H) carrying triantennary N-glycan at Asn30, fucosylation at Asn13 and
core 2 O-glycans at Ser127, Ser132 and/or Ser138 (Figure 2b) [42] was discovered by Professor Cole
in 1997 [43].
Hyperglycosylated hCG forms are not only indicators of the presence of cancer, but also enhance
both cancer growth and cell invasion when supplemented into cell lines [44,45]. Since hCGβ-H and
hCG-H induce the malignancy of different cancer types, the B152 antibody recognising these two
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forms of hCG appears to be a promising biomolecule applicable to the therapeutic treatment of the
disease [41]. Hyperglycosylated forms of hCG are currently defined as drivers for most or possibly all
human cancers [46].Diagnostics 2019, 9, 156 4 of 19 
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Figure 2. (a) A typical structure of hCG with 2 N-glycans in the α subunit of the hCG (hCGα) at Asn52
and Asn78, while theβ subunit of hCG (hCGβ) contains 2 N-glycans (Asn13 and Asn30) and 4 O-glycans
(Ser121, Ser127, Ser132 and Ser138). The glycan composition shown here for hCGβ is a typical structure
present in the protein from a pregnant woman; (b) The structure of β subunit of hyperglycosylated
hCG (hCG-H) i.e., hCGβ-H present in various malignancies including TC. While type 2 O-glycan
is present in both forms of hCGβ and hCGβ-H at Ser121, hCGβ-H contains type 2 O-glycans at all
O-glycan sites (Ser127, Ser132 and Ser138). The differences in the glycan composition between hCGβ
and hCGβ-H are highlighted by a red ellipse. Abbreviations used: GlcNAc = N-acetylglucosamine,
Man = mannose, Gal = galactose, SA = sialic acid, Fuc = fucose and GalNAc = N-acetygalactosamine.
Redrawn from [35], Copyright (2016), with permission from Elsevier.
The protein, hCG and its various forms can be divided into several groups:
(A) two types when considering the binding preference [41]:
• binding to LH/hCG hormone receptor (hormone hCG, a normal form of hCG);
• binding to TGFβ-II receptor (hCG-H or hCGβ-H).
(B) four molecules, when considering the glycosylation pattern containing [47,48]:
• four biantennary N-glycans, three type 1 O-glycans (tri- and tetra-saccharides), one type 2
O-glycan (hCG);
• four biantennary N-glycans d four type 2 O-glycans (penta- and hexa-saccharides)
(placental hyperglycosylated hCG);
• triantennary N-glycans on β-subunit and type 2 O-glycans (extravillous cytotrophoblast
hyperglycosylated hCG and cancer hyperglycosylated hCG);
• N-acetylgalactosamine-sulphate terminating N-glycans and type 1 O-glycans (sulphated
hCG hormone).
(C) seven semi-independent molecules, when considering functional roles [41]:
• placental hCG (controlling pregnancy);
• placental autocrine hyperglycosylated hCG (start placentation during pregnancy);
• pituitary sulphated hCG (present during ovarian steroidogenesis, ovulation & luteogenesis);
• foetal hCG horm ne (promoting foetal organ growth);
• ovar an hype glycosylated hCG (driving the final proteolytic enzy atic step during ovulation);
• hCG-H (trophoblastic tumours);
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• hCGβ-H (non-trophoblastic tumours).
(D) significant structural variability involving numerous isoforms combining glycosylation (14 major
variants for hCGα and 12 major variants for hCGβ) [35,49,50] and structural (nicked forms of
hCG, hCGβ, hCG-H, hCGβ-H; hCG forms without a terminal CTP tail (β113-145 containing all
4 O-glycans); β-core fragment (β6-40 and β55-92 linked by a disulphide bond)) variations [35,41].
Hyperglycosylation (a change of type 1 O-glycans into type 2 O-glycans) affects protein-folding,
resulting in the exposure of an otherwise hidden sequence, which is nicked/cleaved at β47-48 by
leukocyte elastase resulting in the dissociation of hCG-H into hCGβ-H [41]. While hyperglycosylated
hCG cannot bind to TGFβ-II receptors directly, hyperglycosylated hCGβ is able to do so [41]. It has
been shown that molecules acting on TGFβ-II receptors induce the production of metalloproteinases
and collagenases and thereby promote cell-to-cell invasion [51]. Multiple studies have also shown
that all malignancies produce either hCGβ (non-trophoblastic cancers) or hyperglycosylated hCG
(trophoblastic cancers including testicular GCTs) [51–53]. Non-trophoblastic cancers do not produce
a dimeric form of hCG, due to the absence of an enzyme, disulphide isomerase, which adds two
disulphide bonds to the β subunit and only this subunit can be recognised by the α subunit to form a
dimer [41]. The protein is present in blood and urine in at least 18 forms and degradation products of
different sizes and levels of glycosylation [40]. The most recent study suggests the presence of a 4th
hCG form, i.e., a sulphated hCG—hormone hCG with N-acetygalactosamine-sulphate terminating
glycan [48]. In addition, there are indications that the automated tests currently in use in clinical
laboratories to determine hCG levels are not optimal. They cannot distinguish between the different
protein forms, or they cannot capture all of them [41].
2.2. α-Fetoprotein (AFP)
Alpha-fetoprotein (AFP; 70 kDa) is a glycoprotein composed of 591 amino acids with different
characteristics, as shown in Table 1. The protein is normally synthesised in the yolk sac, liver and
intestine and serves as a major serum-binding protein. AFP has 3 isoforms: L1 is produced in
non-neoplastic liver disease, L2 is produced in yolk sac tumours, and L3 is produced in hepatocellular
carcinoma and hepatoblastoma [54]. High levels are observed physiologically in the first years of life,
in infective-degenerative liver diseases and during regeneration of the liver after toxic damage, in yolk
sac tumours, embryonal carcinoma, but also in hepatocellular carcinoma (HCC). High biomarker levels
are noted in 50–70% of patients with non-seminomas, thus AFP is the most commonly elevated tumour
marker in TC [55]. Pure tumours (TC choriocarcinoma and seminoma) do not have the potential to
produce AFP. The half-life of AFP is 5–7 days, which is approximately 5-times higher in comparison
with hCG.
The serological AFP level is routinely used in diagnosis, therapy monitoring and in a follow-up
process for patients with GCTs. The level of AFP during patient-monitoring, however, can be difficult
to interpret since elevated AFP can result from non-tumour liver activity, such as hepatotoxicity due to
chemotherapy [56].
2.3. Lactate Dehydrogenase (LDH)
Lactate dehydrogenase (LDH; 134 kDa) is a cytoplasmic enzyme produced by many types of
tissues, including muscle (skeletal, smooth, cardiac), liver, kidney and brain [18,57,58]. LDH is a
tetrameric protein composed of two structurally different subunits. In serum, the enzyme is present
in a form of 5 isoenzymes, which concentration correlates with the number of gene copies in a short
arm of chromosome 12p, where they are coded [18,37,59]. Isoenzyme LDH-1 is the most frequent
form of LDH present during increased levels of LDH [18,37,60]. Although 40–60% of men with TC of
germ cell etymology have elevated LDH, this marker may be considered as an alternative serological
marker due to the relatively low specificity for GCTs compared to AFP and hCG [18,37,58,61]. hCG and
AFP are produced by tumour cells, but an increased level of LDH in serum is a result of cell damage,
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as well [57]. Nonetheless, there are some correlations between LDH levels and the survival of TC
patients [37,62]. LDH is one of the three sole serum markers currently used for risk stratification in TC,
based on the International Germ Cell Consensus Classification (IGCCC) criteria [32,63]. LDH has a
limited sensitivity and specificity for seminoma. It is increased in approximately 80% of advanced
seminomas. An elevated LDH level was observed in 60% of advanced non-seminomas with a value
higher than 2000 U/L, indicating an advanced disease and/or disease recurrence [18,58,64]. LDH assays
determine activity not quantity, therefore the differences in values can be expected between several
methods applied for its activity assays [18].
2.4. Other TC Biomarkers
A recent review made the following conclusion: “Having systematically reviewed the available
literature, we found surprisingly little evidence to guide optimal testing with biomarkers (AFP, hCG
and LDH) routinely used during follow-up for testicular cancer recurrence” [65]. Due to all these
reasons, there is still a substantial effort to find novel biomarkers which are more reliable for example,
for disease prognosis [66] or diagnostics (DNA methylation, microRNAs, proteins) [17,67–70].
Neuron-specific enolase, an isoenzyme of the glycolytic enzyme 2-phospho-d-glycerate-hydrolase, is
elevated in approximately 30–50% of patients with seminoma, specifically in metastatic stages. Moreover,
the protein level can be increased in patients with normal hCG and LDH concentration [17,71,72]. On the
other hand, it is not a reliable marker due to the high false-positive rate [73]. Elevation was observed also
in other conditions [24,74].
Another TC biomarker is a placental alkaline phosphatase. There are 2 genes coding the proteins
with alkaline phosphatase activity, the placental (PLAP) and germ cell enzyme (also noted as a
placental-like alkaline phosphatase) [75]. The enzyme is physiologically expressed in foetal germ
cells and in infants [18]. Therefore, the staining results in the first years of postnatal life must be
interpreted with caution [25]. The protein is also produced ectopically by a variety of malignant
tumours [76,77]. The elevated protein level is observed in approximately 80% of TC patients [78] and
the most frequently in seminoma TC (60–70%) [79]. Despite the low false-positive rates (1.6%), its
potential for disease monitoring is complicated by the fact that its serum level can increase up to 10-fold
by smoking [26,65,78,79].
TC cells express several high molecular weight glycoproteins. One of these antigens, sialylated
keratin sulphate proteoglycan, can be detected by monoclonal antibody against TRA-1-60
(podocalyxin) [80,81]. It is expressed by embryonal cancer, seminoma and carcinoma in situ of
the testis [82,83]. The study showed that the antigen is expressed in approximately 80% of patients with
advanced embryonal carcinoma. Although its level decreases during chemotherapy, 15–30% patients
do not have normalized levels after therapy [84]. A low assay specificity limits its wider use [17,18,37].
From novel TC biomarkers discovered thus far, the following biomolecules/cells can be listed:
microRNAs [26,85], DNA methylation [86], circulating tumour cells [26], circulating DNA [26], various
proteins [26]. DNA-based biomarkers can be used for non-invasive diagnostics due to the presence of
different DNA types in blood stream [87]. An increased level of circulating tumour DNA was observed
in men with TC and circulating tumour DNA can distinguish patients with cancer from healthy ones
(88% sensitivity and 97% specificity), also in cases with a normal level of conventional markers [88,89].
DNA present in blood is produced by different organs/cells and this is why by DNA analysis, a clearer
and more complex picture about the substantial heterogeneity of TC can be obtained. On the other
hand, DNA is unstable in the blood stream and it is rapidly cleared. Therefore, the use of this marker for
diagnosis requires high-throughput and sensitive techniques [17]. The largest potential from novel TC
biomarkers have microRNAs associated with different types of TC [68]. MicroRNAs are highly stable
versions of the RNA, modulating protein-coding genes expression. MicroRNAs act either as oncogenes
or tumour-suppressor genes. In cancer, they are dysregulated and their profiles can show the origin of
tumours. Due to these properties, microRNAs are promising biomarkers for cancer monitoring [32].
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For example, TC patients negative for microRNA-371a-3p had a better progression-free survival and
an overall survival compared to the TC patients with microRNA-371a-3p present in serum [90].
None of the mentioned markers are universal and specific. Recently, it was discovered that
extracellular vesicles, such as exosomes, can be a rich source of various types of biomarkers as detected
for various types of urological tumours [91]. As exosomes so far have not been applied for TC
diagnostics and/or monitoring, their application in the discovery for novel and robust TC biomarkers
is extremely exciting.
3. Glycans as TC Biomarkers
The changes/alterations in glycosylation can be successfully applied to the discovery of novel
cancer-related biomarkers. It is estimated that 70+% of all proteins are post-translationally modified
by glycosylation with the involvement of glycans in cancer development and progression [92–98].
A recent paper in Science showed that, for reliable and accurate diagnostics of cancer at an early
stage, multiple analytes need to be determined in serum, including the levels of several proteins and
cell-free DNA [99]. Although, in this pioneering study [99], glycan analysis was not implemented
for cancer diagnostics, a forthcoming study showed that glycan analysis can deliver more reliable
results with excellent discrimination between indolent localised prostate cancer and an aggressive
non-localised form of the disease [100]. Accordingly, the sections below focus on an evaluation of the
clinical performance characteristics of glycans as TC biomarkers.
3.1. Performance of Glycosylated hCG as a TC Biomarker
The performance of hyperglycosylated hCG was evaluated in order to discriminate between
various types of cancer based on the data presented in Cole’s paper [51]. This is shown in the
Supplementary file (Table S1).
hCG from urine samples of pregnant women and patients having choriocarcinoma (n = 3),
invasive mole (n = 3), male GCT (n = 2) and a non-pregnant control were glycoprofiled using
several lectins [101]. The results showed that the following lectins were able to distinguish hCG from
GCT patients when compared to the non-pregnant control: Galanthus nivalis agglutinin, Phaseolus
vulgaris leukoagglutinin (recognising branched glycans), Pisum sativum agglutinin (recognising
glucose/mannose), Ricinus communis agglutinin (recognising terminal galactose), Maackia amurensis
agglutinin II (recognising 2,3-linked sialic acid), Sambucus nigra agglutinin (binding to 2,6-linked sialic
acid) and wheat germ agglutinin (recognising sialic acid and β1,4-GlcNAc). The authors acknowledge
that the glycan composition on hCG from cell lines, urine and serum might be different due to the
partial hCG degradation during renal secretion [101]. This lectin-based glycoprofiling of hCG can
complement the use of antibody B152, raised against type 2 O-glycan on Ser132 of hCG (hCG-H or
hCGβ-H) [101].
hCGβ isolated from the urine of patients with non-seminomatous TC (n = 2, stages 1 and 3),
choriocarcinoma (n = 1), invasive mole (n = 1), pregnant women (n = 2) and a choriocarcinoma cell
line (n = 1) was applied to the analysis of site-specific glycan structures using liquid chromatography
combined with mass spectrometry [102]. With regard to N-glycan analysis, triantennary glycans and
fucosylation increased at Asn13 and Asn30 of hCGβ isolated from the cancer samples. With regard
to O-glycans, type 2 O-glycans, in particular, were enriched at Ser127 and Ser132 in cancer and
especially, in TC. The other important difference between O-glycosylation at Ser127 and Ser132 is a
complete absence of short O-glycans, like Tn (N-acetygalactosamine attached to serine/threonine),
T (galactose-β-1,3-N-acetygalactosamine attached to serine/threonine) and sialyl T antigen on hCGβ
from TC patients in comparison with an invasive mole patient and pregnant women. The authors
suggest that these glycan differences might facilitate the application of lectins to the diagnosis of
malignancies (including TC), but a larger number of samples need to be analysed to confirm such
results [102].
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The study led by Lempiainen found that non-seminomatous germ cell tumours (NSGCTs)
produced hCG-H when examined in tissues [103]. hCG-H was absent in seminoma, spermatocytic
seminomas, pure teratomas, non-seminoma or yolk sac. This might aid in discriminating between
seminoma and NSGCT with a sensitivity of 23% and specificity of 100% for NSGCT among patients
with TC. The hCG-H-staining in tissues correlated very well with a serum concentration of hCG-H.
In addition, the staining intensity of hCG-H correlated well with the disease stage, but did not
correlate with progression-free survival [103]. Another study from the same group concluded that the
measurement of hCG-H in pre-operative NSGCT and seminoma patients correlated well with hCG
and hCGβ [104]. Moreover, hCG-H had the same prognostic value as hCG and hCGβ and the levels of
hCG-H, hCG and hCGβ followed the disease course (during follow-up and in relapse) in the same
way. Accordingly, it was concluded that hCG-H did not provide any additional clinical information
over that provided by hCG and hCGβ. There are limitations in these two studies led by Lempiainen,
such as the low number of samples investigated for some disease conditions, the fact that the hCG-H
antibody detected hCGβ-H in only 25% of cases and that the limit of detection for hCG-H is quite high
(2 pM) [104].
3.2. Performance of Glycosylated AFP as a TC Biomarker
It is apparent that the most appropriate lectins to interact with AFP’s glycans are Concanavalin A
(Con A, a mannose binding lectin) and Lens culinaris agglutinin (LCA, recognising α1,6-fucose). In the
early experiments, Con A affinity chromatography exhibited different binding to AFP isolated from
amniotic fluid, foetal serum, liver cancer serum and yolk sac tumour serum [105]. The different fractions
of AFP bind to specific lectins [106]. Studies suggested that a lectin-reactive AFP form indicated a high
risk of tumour recurrence [107,108]. Fraction AFP-L3% (i.e., AFP fraction binding to Lens culinaris
agglutinin—LCA) may be used to distinguish between benign and malignant tumours (i.e., a predictive
biomarker) [109], but the same form of AFP has been produced by HCC [110]. Since AFP present in
the serum of GCT patients has additional GlcNAc linked to the β-mannose core of the glycan (i.e.,
a bisecting glycan as shown in Figure 3a for NSGCT) patient [54], the binding of Con A is blocked.
Hence, it is possible to calculate the Con A binding ratio (Con A-BR) as the percentage of AFP not
bound to Con A [111].
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By applying Con A-BR >15%, it was possible to distinguish patients with tumour and non-tumour
liver disease from patients with GCT with a sensitivity of 98% and specificity of 98%, using a cut-off
value of 15%, while the sensitivity was 100% and specificity 62% respectively, for a cut-off value
of 10% [115]. In the next study by Mora’s group, 50 GCT patients with n i crease of >20% in the
AFP level during chemotherapy or f llow-up, were investigat d to d termine whether elevated AFP
indic GCT progr ssion or a hepatic dise se [115]. The results ex ibit a sensit v y of 96% and
specificity of 0% for the measurement of the AFP level, w ile Con A-BR provided a sensitivity of 92%
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and specificity of 100% [115]. The reason why Con A-BR cannot be applied to the diagnostics of GCT
is that the Con A-BR ratio was very similar for NSGCT patients (12–43%) and for patients with gastric
carcinoma (18–48%), while significantly different for patients with liver disease (2–8%).
An analysis of AFP-L3%, a fraction of AFP binding to LCA, appears to be a better biomarker
for identifying a recurrence of the yolk sac tumour than an analysis of AFP in serum for a neo-natal
patient [116]. The 1st resection was incomplete due to a massive haemorrhage during the operation
and AFP-L3% better indicated the recurrence of the disease and also successful chemotherapy and a
subsequent resection than the AFP level analysis. The other very important outcome of using AFP-L3%
is that neonates without any disease, but having high AFP levels, were correctly identified as healthy
by measuring AFP-L3%.
The case of a 35-year-old man diagnosed with a testicular embryonal carcinoma was
monitored [117]. After orchiectomy, the AFP levels were persistently elevated but a very low AFP-L3%
indicated no residual or recurrent tumour. The patient has been free from disease for 3 years following
the operation and the AFP levels have remained in the range of 19–27 ng/mL.
An AFP-L3% assay might provide better information about future disease recurrence/relapse for
NSGCT, teratocarcinoma and embryonal cell carcinoma adult patients than the AFP level in serum,
as suggested by Kawai et al. [107]. The AFP-L3% assays need to be implemented with caution as
there were cases when such an assay failed to detect tumour activity and was negative in two purely
seminoma patients with AFP at the cut-off value. However, the authors also conclude that AFP-L3% is
a sensitive and specific marker of TC, especially in cases where the AFP level is only slightly increased
or at the cut-off value of 20 ng/mL [107]. Another study indicates that AFP-L3% with a value of >50%
correctly identified 96% of patients with various types of NSGCTs, i.e., embryonal carcinoma (n = 9),
yolk sac tumour (n = 4), a mixed type without seminomas (n = 5) and a mixed type with seminoma
(n = 7), irrespective of the AFP level in serum [109]. Moreover, in nine patients whose sera were
sequentially measured, AFP-L3% was highly effective in the detection of two residual tumours, one
recurrence and one false positive case [109].
The percentage of AFP reactive with three lectins LCA, Phaseolus vulgaris leukoagglutinin and
Ricinus communis agglutinin using a radioimmunoassay showed a significant difference in the glycan
composition of AFP from patients with GCT (n = 7) in comparison with AFP from embryonal fluids
(n = 11) [118].
Johnson et al. analyzed the glycan composition of AFP isolated from the sera of 2 patients
with HCC (hepatocellular carcinoma) and 2 patients with NSGCT [113] and, in a second study, from
12 HCC patients and from 1 NSGCT patient [114]. These studies identified different glycan quantities
of AFP depending on the disease (see Figure 3). The authors claim that they chose samples with a
high AFP level for analysis, and it is uncertain whether the differences observed in the AFP’s glycan
composition isolated either from HCC or from NSCGT patients would be the same/similar if low
AFP level samples were included in the studies. Thus, in the next studies, more samples need to be
included and investigated. Besides having biantennary glycans on AFP as shown by Johnson [113,114],
the Uniprot database (https://www.uniprot.org/uniprot/P02771) suggests the presence of triantennary
and/or branched N-glycans, as was confirmed by Aoyagi et al. [112] and Tsuchida et al. [54].
3.3. Analysis of Glycans in Serum
Serum N-glycans were examined for the diagnostic and prognostic ability in GCTs. The authors
performed a structural analysis of 103 age adjusted healthy volunteers and 54 patients with different
types of TC. Five glycan structures were applied as diagnostics biomarkers with AUC > 0.75.
The discriminative analysis of glycans as a prognostic biomarker was significant and the AUC value
was 0.87, when using the N-glycan score (4 glycans with m/z 2890, 3195, 3560, and 3865). Importantly,
the N-glycan score correctly identified 10 out of 12 (83%) patients with negative conventional tumour
markers. Moreover, six different glycans were identified for prognostics (AUC = 0.89) and four
glycans for relapse purposes. A survival analysis was examined during 20 months and a high value of
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identified glycans (mostly fucosylated and sialylated glycans) was associated with a poor prognosis.
A summary of glycan structures applicable as diagnostic or prognostic biomarkers is summarised in
Figure 4. The study also reached a conclusion that IgG is not a protein carrying candidate N-glycans,
but a carrier protein was not identified [119].Diagnostics 2019, 9, 156 10 of 19 
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3.4. Application of Lectins for Analysis in Tissues
Lectin histochemistry found its way for TC diagnosis and staging [120,121]. These studies have
shown that different cells at different stages react with different lectins. Various types of NGCs have
similar reactivity with lectins Con A, LCA, wheat germ agglutinin (WGA) and RCA I, while lectins
peanut agglutinin (PNA), soybean agglutinin (SBA), Helix pomatia agglutinin (HPA) exhibited stronger
binding towards normal cells. These findings suggested the potential use of lectins in histological
identification of tumours [120,122].
The tissue sections from 5 different organs (brain, liver, kidney, spleen and testis) from two mice
were analysed using lectin microarrays [123]. The results suggest that the overall glycome pattern of
testis is completely different, when comparing with other tissues with significantly different clustering
using a principal component analysis and O-glycosylation (Figure 5). The results also showed that the
localization of O-glycan binders was limited at the inner part of seminiferous tubules with different
staining patterns [123]. The differences in the glycan profiles of various structures within testis tissues
suggests that lectins have a potential to be applied to detect malignant processes associated with TC.
When changes in the profile of simple mucin-type O-glycans (Tn, sialyl-Tn and T antigens) were
investigated in tissues of human testis and testicular neoplasm, it was found that normal testis showed
a restricted pattern when considering O-glycosylation and/or the expression of six polypeptide GalNAc
transferases [124]. On the other hand, profound changes were associated with neoplasia in malignant
germ cells [124].
Diagnostics 2019, 9, 156 11 of 19
Diagnostics 2019, 9, 156 11 of 19 
 
 
Figure 5. Two-dimensional analysis of the normalized lectin microarray data from the 182 tissue 
fragments. The 182 samples are listed in columns and the 45 lectins are listed in rows. The colour and 
intensity of each square indicate the lectin signal levels in specific tissue fragments (Red, high; green, 
low; black, medium). Reprinted from ref. [123]. 
3.5. Analysis of Expression Of GLycan-Processing Enzymes 
An immunohistochemical analysis of the core 2 N-acetylglucosaminyltransferase-1 (C2GnT-1, 
responsible for branching of O-glycans) level in GCT tissues revealed a slight positivity in stage I 
disease (29.5%, 21/71) compared to more advanced disease stages (84.7%, 50/59) (p < 0.001). 
Moreover, C2GnT-1-positive GCT patients with stage I seminoma had a higher risk for recurrence of 
the disease (p < 0.001). The results obtained strongly suggest that C2GnT-1 enhances the metastatic 
potential of TGCT and may be a reliable biomarker to identify the aggressive potential of testicular 
GCT [125]. 
An immunohistochemical analysis of orchiectomy specimens of 130 patients with TGTC 
revealed the under-expression of N-acetylglucosaminyltransferase-V (GnT-V), responsible for β1-6 
branching during carcinogenesis and the progression of TGCT [126]. This branching is recognised by 
Phaseolus vulgaris leukoagglutinin (PHA-L) [127]. This is why the GnT-V enzyme is considered as a 
promising recurrence predictor for stage I NSGCT. The N-linked structural analysis of glycans 
released from the tissues allowed the conclusion that besides GnT-V, GnT-III (responsible for 
production of bisecting N-glycans) is also downregulated. On the other hand, a structural glycan 
analysis revealed the up-regulation of GnT-IV enzyme and this is why the detection of these 
additional two enzymes can also be applied for disease monitoring [126].  
The group led by Professor Gabius discovered that by using a set of lectins and 
neoglycoconjugates conjugated to bovine serum albumin, it is possible to differentiate between 
seminoma, embryonic carcinoma and choriocarcinoma using human tissues [128]. 
3.6. Analysis of Glycan Binding Proteins 
Galectins are composed of approximately 130 amino acids with a β-galactoside-binding ability. 
Fifteen different types of mammalian galectins were identified. For diagnostic purposes, galectin-1 
and galectin-3 are the most suitable. Galectin-1 is abundant in most organs: muscle, heart, liver, 
prostate, lymph nodes, spleen, thymus, placenta, testis, retina, macrophages, B-cells, T-cells, 
tumours. Galectin-3 is localized mainly in tumour cells, macrophages, epithelial cells, fibroblasts, 
activated T cells [129]. Galectin-3 is expressed in a variety of tissues and plays a role in diverse 
biological events, such as embryogenesis, angiogenesis, adhesion, cellular proliferation, apoptosis 
and the modulation of the inflammatory process and immune response. Galectin-3 has also been 
implicated in tumour progression and metastasis in a variety of human cancers, such as thyroid, 
pancreas and breast carcinomas [130]. In addition, galectin-3 expression has been reported in pig, rat 
and human Sertoli cells [131].  
Figure 5. Two-dimensional analysis of the normalized lectin microarray data from the 182 tissue
fragments. The 182 samples are listed in columns and the 45 lectins are listed in rows. The colour and
intensity of each square indicate the lectin signal levels in specific tissue fragments (Red, high; green,
low; black, medium). Reprinted from ref. [123].
3.5. Analysis of Expression Of GLycan-Processing Enzymes
An immunohistochemical analysis of the core 2 N-acetylglucosaminyltransferase-1 (C2GnT-1,
responsible for branching of O-glycan ) level in GCT tissues revealed a slight positivity in stage I
di ease (29.5%, 21/71) compared to more advanced disease stages (84.7%, 50/59) (p < 0.001). Moreov r,
C2GnT-1-positive GCT patients with stage I seminoma had a higher risk for recurrence of the disease
(p < 0.001). The results obtained strongly uggest that C2GnT-1 en nces the metastatic potential f
TGCT and may be a reliable biomarker to i entify the ag r sive potential of testicular GCT [125].
An immunohistochemical analysis of orchiectomy specimens of 130 patients with TGTC revealed
the under-expression of N-acetylglucosaminyltransferase-V (GnT-V), responsible for β1-6 branching
during carcinogenesis and the progres on of TGCT [126]. This branching is recognised by Phaseolus
vulgaris leukoagglutinin (PHA-L) [127]. This is why the GnT-V enzyme is considered as a promising
recurrence predictor for stage I NSGCT. The N-linked structural analysis of gly ans released from the
tissu s allowed th conclusion that besides GnT-V, GnT-III (responsible for production of bisecting
N-glyca s) is also downregulated. On the other hand, a structural gly an an lysis revealed the
up-regulati n of GnT-IV enzyme and this is why the detection of these additional two enzymes can
als be applied for disease monitoring [126].
The group le by Professor Gabius discovered that by using a set of lectins and neoglyc conjugates
conjugated to bovine serum lbumin, it is possible to different ate between seminoma, embryonic
carcinoma and choriocarcinoma u ing human tissues [128].
3.6. Analysis of Glycan Binding Proteins
Galectins are composed of approximately 130 amino acids with a β-galactoside-binding ability.
Fifteen different types of mammalian galectins were identified. For diagnostic purposes, galectin-1
and galectin-3 are the most suitable. Galectin-1 is abundant in most organs: muscle, heart, liver,
prostate, lymph nodes, spleen, thymus, pla enta, testis, r tina, macroph es, B- ells, T-c lls, tumours.
Galectin-3 is localized ainly in tumour cells, macrophages, epithelial cells, fibroblasts, ctivat d
T cells [129]. Galectin-3 is expressed in a variety of tissues and plays a role in diverse biological event ,
s ch as embryogenesi , angiogenesis, adhesion, cellular proliferation, apoptosis and the modulation
of the inflammatory process and immune re ponse. G lectin-3 ha al o been implicated i tumour
pr gression a d metast is in a variety of human cancers, such as thyroid, pancreas and breast
carcinomas [130]. I addition, g lectin-3 ex ression has been reported in pig, rat a d hum n Sertoli
cells [131].
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Three types of galectins (galectin-1, -3, -8) and anti-Ki-67, anti-bcl-2 and anti-p53 were used to
measure the distance between the tumour cells and cluster radii in primary testis carcinomas lung
metastases [108]. A multivariable analysis of total survival in 34 patients shows a positive correlation of
the distance between the tumour cells expressing galectin-1, a negative correlation of cluster radius of
tumour cells expressing galectin-3, a positive correlation of distance between lymphocytes and tumour
cell expressing galectin-8 and a negative correlation between lymphocytes and tumour cell expressing
a high level of galectin-8. The expression of galectin-3 binding sites in the tissues of TC patients (n = 34)
means a better survival rate compared to tissues not expressing glycans binding galectin-3 [108].
In malignant testicular Sertoli cell tumours, the expression of galectin-3 is down-regulated while,
in benign Leydig cell tumours, this expression is maintained, indicating the possible implication of this
gene in the development of more aggressive testicular sex cord stromal tumours [129]. In contrast to
sex cord stromal tumours, Gal-3 expression is up-regulated in testicular germ cell tumours [129].
Galectin-3 is considered a marker of aggressiveness in TC [130]. While the gene is down-regulated
in normal adult testis, a higher amount was observed for seminomas GCT and much higher for
non-seminomas GCT tissue. A higher galectin-3 mRNA was observed in the non-seminomas GCT cell
line (NCCIT) compared to the seminoma GCT cell line (JKT1) [130].
4. Conclusions
The review reveals the true potential of glycan profiling to become powerful TC biomarkers
besides the TC biomarkers already described and applied, such as circulating DNA, microRNA, various
types of proteins and circulating tumour cells. In particular, the glycoprofiling of two TC biomarkers,
like hCG and AFP, would appear to be a promising area for the discovery of novel TC biomarkers.
With regard to changes in the glycan composition of hCG, the hyperglycosylated form of hCG or
hCGβ (i.e., transformation of type 1 O-glycan into type 2 O-glycan on Ser132 of the β-subunit of hCG),
in particular, was investigated as a promising TC biomarker for distinguishing from other types of
cancer (Table S1) for potential diagnostic purposes. Only two studies, in addition to the investigation
of hCG-H or hCGβ-H, have been published to date focusing on other glycan parts of hCG. Accordingly,
it can be stated that an analysis of the changes of the other three O-glycans (Ser121, Ser127 and Ser138)
and four N-glycans, so far underexplored, is worth investigating to identify additional promising
glycans as TC biomarkers for diagnostic and prognostic purposes and for disease recurrence evaluation.
The glycoprofiling of AFP using two lectins, LCA and Con A, can provide useful information as
to whether the elevated AFP is of testicular or hepatocellular origin. Additionally, lectin-assisted AFP
assays have proven to be very useful for the monitoring of TC recurrence, the success of chemotherapy
and in the identification of false positive cases. Lectins, other than these two, need to be integrated into
assay formats to reveal the true potential of glycans as TC biomarkers.
It can be expected that an analysis of glycan changes per se will not deliver reliable results for
diagnostic and prognostic purposes and for recurrence evaluation, but might be a desirable solution
in combination with traditional serological biomarkers as shown in Table S1 or with other novel
serological biomarkers (circulating DNA, microRNA, circulating tumour cells, etc.).
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